Genexine (Korea) Investor Sentiment

095700 Stock  KRW 5,730  200.00  3.37%   
About 62% of Genexine's investor base is looking to short. The analysis of current outlook of investing in Genexine suggests that many traders are alarmed regarding Genexine's prospects. The current market sentiment, together with Genexine's historical and current headlines, can help investors time the market. In addition, many technical investors use Genexine stock news signals to limit their universe of possible portfolio assets.
  
over two months ago at news.google.com         
Genexine KOSDAQ095700 shareholders incur further losses as stock declines 14 percent this week, taki...
Google News at Macroaxis
over three months ago at news.google.com         
We Think Genexine Has A Fair Chunk Of Debt - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
We Think Genexine Has A Fair Chunk Of Debt - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
Genexine, EPD Biotherapeutics to merge for new protein degraders - BioWorld Online
Google News at Macroaxis
over three months ago at news.google.com         
Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline - Yahoo F...
Google News at Macroaxis
over three months ago at news.google.com         
Genexine to merge with EPD Biotherapeutics to enhance PROTAC technology and drug pipeline - KBR
Google News at Macroaxis
over six months ago at news.google.com         
Genexine Has Debt But No Earnings Should You Worry - Simply Wall St
Google News at Macroaxis
over a year ago at news.google.com         
Lumos lights up pediatric growth hormone deficiency with oral ... - BioWorld Online
Google News at Macroaxis
over a year ago at news.google.com         
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoeti...
Google News at Macroaxis
over a year ago at news.google.com         
Genexines long-acting growth hormone meets Phase 3 primary endpoint - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Lymph Node Classification May Help Prognosticate in Esophageal ... - Cancer Network
Google News at Macroaxis
over a year ago at news.google.com         
Genexine Abstract on GX-188E and GX-I7 Triple Combination Therapy in HNSCC Is Released at 2023 ASCO ...
Google News at Macroaxis
over a year ago at news.google.com         
Circulating Tumor DNA as a Predictive Biomarker for Clinical ... - Cancer Network
Google News at Macroaxis
over a year ago at news.google.com         
ZolbetuximabmFOLFOX6 Prolongs Survival in Locally Advanced ... - Cancer Network
Google News at Macroaxis
over a year ago at news.google.com         
FDA Accepts sBLA for PembrolizumabChemo in Gastric or GEJ ... - Cancer Network
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Genexine that are available to investors today. That information is available publicly through Genexine media outlets and privately through word of mouth or via Genexine internal channels. However, regardless of the origin, that massive amount of Genexine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Genexine news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genexine relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genexine's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genexine alpha.

Genexine Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Genexine Stock analysis

When running Genexine's price analysis, check to measure Genexine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genexine is operating at the current time. Most of Genexine's value examination focuses on studying past and present price action to predict the probability of Genexine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genexine's price. Additionally, you may evaluate how the addition of Genexine to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities